Back to School 2020
Novartis’ Narasimhan sees unexpected lessons from COVID-19, and anticipates more: a BioCentury audio interview
Novartis CEO reflects on how the pandemic has changed drug development for large biopharmas
Novartis CEO Vas Narasimhan reflects on how the pandemic has changed drug development for large biopharmas.
The digital transformation of drug development that is being accelerated in response to the pandemic will continue, according to Novartis CEO Vasant Narasimhan. However, there’s still a learning curve on whether the clinical and preclinical shortcuts introduced with the pandemic can be used more routinely.
In a BioCentury 2020 Back to School audio interview, Narasimhan discussed the legacies of the pandemic and how they might shape the decisions made by large biopharmaceutical companies such as Novartis AG (NYSE:NVS; SIX:NOVN). The interview was one of a series with key industry leaders as part of BioCentury’s Back to School 2020 multimedia content (see Cover Story: “The Imperative of COVID-19”).
Heavy investment in digital technologies made it possible during the pandemic for Novartis to “go from the concept of a clinical trial to the first patient, first visit, in six weeks,” said Narasimhan.